Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations by Tjitra, Emiliana et al.
  
10.1128/AAC.46.12.3947-3953.2002. 
2002, 46(12):3947. DOI:Antimicrob. Agents Chemother. 
Nicholas M. Anstey
Emiliana Tjitra, Joanne Baker, Sri Suprianto, Qin Cheng and
 
 MutationsPlasmodium vivax dhfr
Vivax Malaria Pilot Studies: Relationship to 
Chloroquine-Sulfadoxine-Pyrimethamine in 
andArtesunate-Sulfadoxine-Pyrimethamine 
Therapeutic Efficacies of
http://aac.asm.org/content/46/12/3947
Updated information and services can be found at: 
These include:
REFERENCES
http://aac.asm.org/content/46/12/3947#ref-list-1at: 
This article cites 39 articles, 24 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 Septem
ber 3, 2013 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2002, p. 3947–3953 Vol. 46, No. 12
0066-4804/02/$04.000 DOI: 10.1128/AAC.46.12.3947–3953.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Therapeutic Efficacies of Artesunate–Sulfadoxine-Pyrimethamine and
Chloroquine–Sulfadoxine-Pyrimethamine in Vivax Malaria Pilot
Studies: Relationship to Plasmodium vivax dhfr Mutations
Emiliana Tjitra,1,2 Joanne Baker,3 Sri Suprianto,4 Qin Cheng,3 and Nicholas M. Anstey2,5*
National Institute of Health Research and Development, Ministry of Health,1 and Directorate-General of Communicable
Disease Control and Environmental Health, Ministry of Health,4 Jakarta, Indonesia, and International Health Program,
Division of Infectious Diseases, Menzies School of Health Research,2 Division of Medicine, Flinders University
Northern Territory Clinical School, Darwin, Northern Territory,5 and Australian Army
Malaria Institute, Enoggera, Queensland,3 Australia
Received 4 June 2002/Returned for modification 5 August 2002/Accepted 5 September 2002
Artemisinin-derivative combination therapies (ACT) are highly efficacious against multidrug-resistant Plas-
modium falciparum malaria. Few efficacy data, however, are available for vivax malaria. With high rates of
chloroquine (CQ) resistance in both vivax and falciparum malaria in Papua Province, Indonesia, new com-
bination therapies are required for both species. We recently found artesunate plus sulfadoxine-pyrimethamine
(ART-SP) to be highly effective (96%) in the treatment of falciparum malaria in Papua Province. Following a
preliminary study of CQ plus sulfadoxine-pyrimethamine (CQ-SP) for the treatment of Plasmodium vivax
infection, we used modified World Health Organization criteria to evaluate the efficacy of ART-SP for the
treatment of vivax malaria in Papua. Nineteen of 22 patients treated with ART-SP could be evaluated on day
28, with no early treatment failures. Adequate clinical and parasitological responses were found by day 14 in
all 20 (100%) of the patients able to be evaluated and by day 28 in 17 patients (89.5%). Fever and parasite
clearance times were short, with hematological improvement observed in 70.6% of the patients. Double (at
positions 58 and 117) and quadruple (at positions 57, 58, 61, and 117) mutations in the P. vivax dihydrofolate
reductase (PvDHFR) were common in Papuan P. vivax isolates (46 and 18%, respectively). Treatment failure
with SP-containing regimens was significantly higher with isolates with this PvDHFR quadruple mutation,
which included a novel T3M mutation at residue 61 linked to an S3T (but not an S3N) mutation at residue
117. ART-SP ACT resulted in a high cure rate for both major Plasmodium species in Papua, though progression
of DHFR mutations in both species due to the continued use of SP monotherapy for clinically diagnosed
malaria threatens the future utility of this combination.
High rates of chloroquine (CQ) resistance and CQ treat-
ment failure have been found in both vivax and falciparum
malaria in Papua Province (formerly Irian Jaya), Indonesia (2,
3, 5, 21, 28, 38), and new combination therapies are required
for each species. Artemisinin-derivative combination therapies
(ACT) are being used increasingly for the treatment of multi-
drug-resistant Plasmodium falciparum malaria (29) because of
their excellent efficacy (23, 31, 39, 41), their ability to slow or
reverse the emergence of resistance (24, 30), and their ability
to reduce malaria transmission (24, 30). Despite the coexist-
ence of falciparum and vivax malaria in many parts of the
world where malaria treatment is usually based on clinical
diagnosis, there have been few studies assessing the efficacy of
artemisinin derivatives in treating vivax malaria and none in
the area of CQ-resistant P. vivax. Studies of artesunate (ART)
monotherapy for P. vivax infection have demonstrated rapid
clearance of fever and parasites (1, 6, 33, 43). However, with its
very short half-life, no ART remains by the time of the first
relapse of P. vivax infection, approximately 3 weeks after treat-
ment begins, resulting in a high frequency of 28-day treatment
failure with ART monotherapy (33). Even fewer data are avail-
able regarding the efficacy of ACT in treating vivax malaria. To
address this deficit, the World Health Organization (WHO)
has called for studies to assess the efficacy of ACT in the
treatment of P. vivax, particularly in areas with CQ-resistant
P. vivax (46). We recently found ART plus sulfadoxine-pyri-
methamine (SP) to be highly effective (96%) in the treatment
of falciparum malaria in Papua, Indonesia (39). As malaria is
frequently diagnosed clinically without microscopic identifica-
tion to the species level, the empirical use of ACT in settings
such as Papua, where both species occur, would require that
ACT be efficacious against both falciparum and vivax malaria.
P. vivax is intrinsically resistant to sulfadoxine and has ac-
quired resistance to pyrimethamine in areas of Southeast Asia
such as Thailand (16, 33). Triple mutations have been found in
P. vivax dihydrofolate reductase (PvDHFR) at positions 57, 58,
and 117. These mutations are associated with lower 48-h par-
asite reduction ratios following monotherapy of P. vivax infec-
tion with SP than are isolates with double mutations (at posi-
tions 58 and 117); however, no differences in cure rates have
been demonstrated (16). Even when P. vivax is sensitive to
pyrimethamine, SP therapy of vivax malaria results in slow
clearance of parasites and fever (9). Therefore, SP is not rec-
ommended as monotherapy for P. vivax in Indonesia (13).
However, when ART is combined with SP, the ART should
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rapidly reduce initial parasite biomass, with SP, a drug with a
longer half-life, eradicating the small residual parasite load at
a time of a persisting adequate concentration in blood (42).
While this should allow for a shorter duration of ART than
occurs when it is used as monotherapy (42), it requires that P.
vivax demonstrate sensitivity to pyrimethamine; data support-
ing this have not been previously available from Papua.
Although the CQ-SP combination was later shown to have
inadequate efficacy for falciparum malaria treatment in Papua
Province (8, 38), it had been considered an option for the
empirical management of malaria in Papua. We therefore un-
dertook small pilot studies using modified WHO criteria to
examine the efficacies of CQ and CQ-SP in vivax malaria
treatment. We then evaluated the therapeutic efficacy of the
ART-SP combination for the treatment of P. vivax malaria in
an open study at Genyem Health Center, located in an area of
Papua with CQ-resistant P. vivax (37).
We used P. vivax isolates from these combination studies to
examine the relationship between mutations in the Pvdhfr gene
and the therapeutic efficacies of SP-containing regimens for
the treatment of vivax malaria.
MATERIALS AND METHODS
Study sites and subjects for efficacy studies. Our open therapeutic efficacy
studies were performed in 1999 at Genyem Health Center, Papua Province, an
area where malaria with year-round transmission is meso-endemic (38, 39). The
pilot CQ, CQ-SP, and ART-SP efficacy studies were performed with patients
with vivax malaria who had been admitted to the center from February to April
1999. Following initial evidence for the efficacy of SP against P. vivax in this
region of Papua, the efficacy study of ART-SP was extended to include a larger
number of patients with vivax malaria, those admitted from August to November
1999.
In the absence of published guidelines for assessing the therapeutic efficacy of
P. vivax treatment, patients with uncomplicated vivax malaria were selected on
the basis of the draft 1997 WHO criteria for assessment of the therapeutic
efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with
low or moderate levels of transmission (44). A minimum of 500 parasites/l was
used as the cutoff for inclusion in the CQ and CQ-SP studies, and 1,000 para-
sites/l was the minimum for the ART-SP study; these are more conservative
levels than the 250-parasite/l cutoff presently recommended in the 2002 WHO
guidelines for the assessment of therapeutic efficacy in vivax malaria (45). The
exclusion criteria were danger signs of severe and complicated malaria, preg-
nancy, lactation, and a history of drug hypersensitivity (44).
Informed consent was obtained from all adult study subjects and from a parent
or guardian for minors. The study was approved by the Ethics Committee of the
National Institute of Health Research and Development, the Indonesian Min-
istry of Health, Jakarta, Indonesia, and the Health Research Ethics Committee
of the Menzies School of Health Research and Territory Health Services, Dar-
win, Australia.
Treatment. In the pilot CQ and CQ-SP studies, treatment of patients with
vivax malaria was randomized by day of attendance at the health center to consist
of either CQ or CQ-SP. Treatment doses were CQ (Resochin; Bayer, Jakarta,
Indonesia) at a base dose of 25 mg/kg of body weight (bw) administered orally
over 3 days, alone or in combination with SP (Fansidar; Roche, New South
Wales, Australia) (one tablet containing 500 mg of sulfadoxine and 25 mg of
pyrimethamine) administered in a single dose on day 0 (based on 1.25 mg of
pyrimethamine/kg of bw) (38). The open pilot study of the therapeutic response
of ART-SP was undertaken with five vivax malaria patients and was then ex-
tended to include another 17 patients with symptomatic infections with P. vivax.
Patients were treated with artesunate (Artesunat [Mekophar, Ho Chi Minh,
Vietnam; 5 patients in the pilot phase] and Artesunate [Mediplantex, HaNoi,
Vietnam; 17 patients in the extension phase]; one 50-mg tablet, 4 mg/kg of bw,
administered in a single oral daily dose for 3 days) plus SP (Fansidar [Roche];
one tablet containing 500 mg of sulfadoxine and 25 mg of pyrimethamine, with
a single oral dose given orally on day 0, based on a dose of pyrimethamine of 1.25
mg/kg of bw). The management of treatment failures was conducted according to
Ministry of Health guidelines (13). Difficulties at the study site in Papua Province
in 1999 prevented the enrollment of additional patients.
Clinical examination, staining of serial thick and thin films, and hemoglobin
level measurements were performed on days 0, 1, 2, 3, 7, 14, and 28 (44).
Giemsa-stained thick and thin films were read by a microscopist with 24 years of
experience from the Indonesian National Reference Centre. Asexual- and sex-
ual-stage parasites were counted for every 200 white blood cells, and parasitemia
was calculated on the basis of a white blood cell count of 8,000/l. A thick film
was considered negative if no parasites were found in 100 high-power fields. Day
0 blood blots were collected on filter paper (39) and stored at 4°C until DNA
extraction.
Assessment. The primary end points were the therapeutic responses based on
parasitological and clinical cure by days 14 and 28, determined by using the 1997
WHO protocol criteria (44).
Secondary end points in the ART-SP efficacy study were (i) fever clearance
time, defined as the time (days) from initiation of treatment to fever clearance
(i.e., patient remained afebrile based on reported history and had an axillary
temperature of 37.5°C on day of follow-up); (ii) parasite clearance time, de-
fined as the time (days) from the initiation of treatment to parasite clearance
(i.e., parasite count fell below the level of microscopic detection); (iii) hemato-
logical recovery, defined as being cured on days 14 and 28, with a hemoglobin
level greater than that on day 0; and (iv) tolerability and safety based on the
incidence of adverse reactions. An adverse reaction was defined as the develop-
ment of any symptom or sign that neither existed before the initiation of treat-
ment nor was a classic symptom or sign of malaria or intercurrent infection.
Additional analyses. Therapeutic outcome was also classified as treatment
failure or adequate clinical and parasitological responses (ACPR) by using the
1997 WHO in vivo criteria for falciparum malaria (44). Treatment failure was
defined as the development of one of the following during the follow-up period
(failure in the first 3 days was considered early treatment failure, and failure from
day 4 to day 28 was considered late treatment failure): danger signs or severe
malaria in the presence of parasitemia with the same species as that on day 0,
parasitemia on day 2 greater than that on day 0, parasitemia on day 3 greater
than or equal to 25% of the day 0 parasitemia, the unscheduled return of the
patient due to clinical deterioration in the presence of parasitemia, and the presence
of parasitemia on any of the subsequent scheduled days of return (day 7, 14, or 28)
with the same species as that on day 0. An ACPR was defined as the patient not
developing any of the criteria of early or late treatment failure, with parasite clear-
ance being confirmed throughout the follow-up period beyond day 3 (44).
Additional subjects included in the genotyping studies. In addition to the
subjects included in the Papuan Province efficacy studies described above, Pvdhfr
genotyping studies were also performed with eight isolates of P. vivax from
Radamata, Nusa Tenggara Timur (NTT), a province to the west of Papua, from
patients treated with CQ in 1998 (all with an ACPR) (37). The sole additional
available Papuan isolate was also genotyped; this isolate was from a patient with
a mixed P. falciparum-P. vivax infection who had had late treatment failure of P.
vivax following treatment in 1999 with SP (37).
Parasite DNA isolation, Pvdhfr amplification, and sequencing. Genomic DNA
was extracted by using Chelex-100 (17). Briefly, 40 l of a 5% Chelex-100
solution, preheated to 80°C, was added to each sample. The samples were heated
to 80°C for 10 min with intermittent vortex mixing. The samples were then
centrifuged for 1 min, and the supernatant was transferred and kept at 20°C
until used. Pvdhfr was amplified with primers PvDHFR1 (5 ATGGAGGACCT
TTCAGATGTATT 3) and PvDHFR2 (5 CCACCTTGCTGTAAACCAAAA
AGTCCAGAG 3). PCR was performed with 75 ng of each primer, 2.5 mM
Mg2Cl, 0.2 mM each deoxynucleoside triphosphate (Promega, Madison, Wis.),
1.25 U of AmpliTaqGold (PE Applied Biosystems), and 2 l of genomic DNA.
The reaction mixture was initially heated at 94°C for 10 min, followed by 40
cycles at 94°C for 50 s, 55°C for 50 s, and 72°C for 50 s. The PCR product was
purified with QIAquick spin columns (QIAGEN, Hilden, Germany) and se-
quenced directly from both directions. A mixed infection was reported when
mixed sequence signals were observed at the specific nucleotide positions where
mutations were observed in an otherwise clean DNA sequence.
Data analysis. Data were entered and analyzed by using Epi-Info, version 6
(10). Differences in proportions with treatment failure were determined by using
Fisher’s exact test.
RESULTS
Therapeutic efficacy. In pilot studies to assess whether SP
added efficacy to treatment of P. vivax with CQ, 19 patients
were randomized to treatment with either CQ (n  9) (stan-
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dard therapy for vivax malaria in Papua Province) or CQ-SP
(n 6), with each group having similar baseline characteristics
(Table 1). Only one (11%) of those treated with CQ had an
ACPR at 28 days (but without hematological recovery), with
two having early treatment failure and six having late treat-
ment failure (total treatment failure with CQ, 89%). In those
treated with CQ-SP, four (67%) had ACPR at 28 days (50%
with hematological recovery), with two (33%) having late
treatment failure (results with CQ versus results with CQ-SP,
P  0.046 by a one-tailed Fisher exact test).
Based on this preliminary evidence for the efficacy of SP, 22
subjects were enrolled in the ART-SP efficacy study (Table 1).
The patient ages and ethnic groups were similar for the pilot
(n  5) and extension (n  17) phases of the study, with
Papuan children comprising 80 and 94% of each phase, respec-
tively. Three of the 22 patients enrolled in the ART-SP study
were excluded: one withdrew consent on day 2, one developed
P. falciparum infection on day 7, and the other moved from the
study site on day 28 (he was included for analysis on day 14 but
excluded from analysis on day 28). Thus, the ACPR rate was
100% (20 of 20) by day 14 and 89.5% (17 of 19) by day 28
(Table 2). No adverse reactions were identified.
Genetic mutations in Pvdhfr. Pretreatment isolates were
available from 31 vivax malaria patients from the Papuan ef-
ficacy studies. The Pvdhfr gene was amplified and sequenced
from 26 patients. As two patients had mixed sequences of dhfr,
28 Pvdhfr genotypes were produced (Table 3). Of these 28
Papuan isolates, only 6 (21%) had wild-type amino acids of
P33, N50, F57, S58, T61, S117, and I173. (Fig. 1 and Table 3).
Double mutations were common (n  13; 46%) and included
combinations of R58 and N117 (n  10), K50 and N117 (n 
2), and L57 and T117 (n  1) (Fig. 1). Quadruple mutations in
the gene encoding PvDHFR (L57, R58, M61, and T117) were
found in 18% of the isolates (Table 4). Two-thirds of the
samples had at least two mutations.
Of the 28 Papuan isolates genotyped, 21 were treated with
an SP-containing regimen (5 with CQ-SP, 15 with ART-SP,
and 1 with SP), with the remainder receiving CQ (Table 3).
Treatment outcome was associated with the number of muta-
tions (Table 4). Only 40% of those with the quadruple muta-
tion had an ACPR to an SP-containing regimen compared with
94% of those with two or fewer mutations (P  0.03; Fisher’s
exact test). The rapid parasiticidal effect of the ART compo-
nent in those treated with ART-SP precluded meaningful anal-
ysis of the effect of the quadruple PvDHFR mutation on par-
asite clearance time. In all five cases with the quadruple
mutation, the mutation at position 117 was S to T, whereas of
the 13 isolates with the double mutation, only 1 had S117T
(P  0.0007; Fisher’s exact test), with the remainder having an
S-to-N mutation at this position.
Novel mutations were found at two residues. The first was a
T-to-M mutation at position 61 (n  5; 19%), which in each
isolate was always linked to the triple mutation F57L-S58R-
S117T, thereby forming a quadruple mutation (Table 3). The
second novel mutation was an N50K mutation in two isolates,
which in each case was linked to an S117N mutation. This was
not associated with treatment failure; however, only one case
was treated with an SP-containing regimen. One isolate had a
P33S mutation, which did not result in treatment failure. Mu-
tations at residue 173 were not detected in any of the isolates
(Table 3). In contrast to the high incidence of multiple muta-
tions in the PvDHFR in Papuan isolates, no mutations were
found in any of the eight P. vivax isolates from NTT Province.
DISCUSSION
This is the first report concerning the efficacy of ACT for
vivax malaria in a region with high rates of CQ-resistant P.
vivax (46). Because of the very short half-life of ART, after 3 to
7 days of the treatment of symptomatic infection, no ART
remains by the time of the first relapse, which in northeastern
Papua occurs in 58% of subjects by day 30 (3, 4). A similarly
high rate of early relapse is found in Thailand (33), and after
clearance of the initial infection, the absence of circulating
TABLE 1. Enrollment characteristics of vivax malaria patients treated with CQ, CQ-SP, and ART-SP in Papua in 1999
Characteristic CQ (n  9)a CQ-SP (n  6)b ART-SP (n  22)
Age (yr) (mean  SD [range]) 8.8 (1–27) 4.3 (1–8) 5.6  6.9 (0.5–30)
Gender (% male) 6 (67) 4 (67) 13 (59)
Ethnic group (% Papuan) 78 100 77
History of prior antimalarial use (%) 33 50 59
Axillary temp (°C) (range) 37.1 (36–38.9) 36.4 (36–36.7) 37.1 (36.0–40.5)
Hemoglobin level (g/dl) (range) 10.7 (6.3–17.7) 8.9 (6.4–12.1) 9.9 (6.6–17.6)
Asexual parasitemia (mean no. of parasites/l) (range) 8,756 (920–25,600) 10,398 (440–38,000) 3,951 (840–17,080)
a Includes three patients with mixed P. falciparum and P. vivax infection.
b Includes two patients with mixed P. falciparum and P. vivax infection.
TABLE 2. Therapeutic efficacy of ART-SP in patients
with uncomplicated malaria
Endpointa No. of patients(n  22)b
% of patients
(95% CI)
Clearance time
(days) (mean 
SD [range])
Primary
Day 14 ACPR 20 100 (83.2–100)
Day 28 ACPR 17 89.5 (66.9–98.7)
ETF 0 0
Day 28 LTF 2c 10.5 (1.3–33.1)
Secondary
FCT 1.4  0.6 (1–3)
PCT 1.1  0.2 (1–2)
Hb 12 70.6 (44.0–89.7)
a ACPR, adequate clinical and parasitological response; ETF, early treatment
failure; LTF, late treatment failure; FCT, fever clearance time; PCT, parasite
clearance time; Hb, hematological response.
b Three patients were excluded from evaluation on days 2, 7, and 28 for all end
points except LTF.
c Late treatment failure occurred on days 21 and 28.
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ART at the time of the first relapse is thought to account for
the high (63%) rate of 28-day treatment failure found when
ART is used alone (33). In a setting where the day 28 relapse
rate was expected to be over 50%, we found a 90% day 28 cure
rate with ART-SP. This suggests that the addition of SP to
ART prevents or delays the appearance of the first relapse of
P. vivax infection in Papua. It is consistent with the hypothesis
that when ART is combined with SP, the ART rapidly reduces
the initial parasite biomass, with SP, the drug with the longer
half-life, eradicating or suppressing both the small residual
parasite load and the emerging relapse parasite load at a time
of a persisting adequate concentration in blood. The rapid
initial fever and parasite clearances seen with ART-SP, similar
to those previously found with ART monotherapy (1, 6, 33,
46), indicate that the addition of ART to SP overcomes the
slow parasite and fever clearances ordinarily seen with SP
monotherapy (9), a major reason underlying recommenda-
tions to avoid the use of SP monotherapy for P. vivax (13).
There is greater difficulty associated with efficacy studies
with P. vivax than with P. falciparum, because of the difficulty in
distinguishing recrudescences from relapses (4). The limita-
tions of our studies in particular included small sample sizes,
FIG. 1. Stepwise drug selection processes in the mutations encoded by the Pvdhfr gene suggested by the observed allele structures in Papuan
genotypes.
TABLE 3. Frequency of pvdhfr-encoded mutations among clinical isolates of P. vivax in Papua
Trial
no.
Sequence polymorphisma at position:
No. of mutations Therapeutic response(SP-containing regimen)b33 50 57 58 61 117 173
G806 P N F S T S I 0 ACPR (CQ-SP)
G903 P N F S T S I 0 LTF (CQ-SP)
G104 P N F S T S I 0 ACPR (CQ-SP)
G2060 P N F S T S I 0 ACPR (ART-SP)
G2069 P N F S T S I 0 ACPR (ART-SP)
G058 P N F S T S/T I Mixed (0 and 1) CQ
G965 P N F S T N I 1 ACPR (CQ-SP)
G359 P N F R T N I 2 CQ
G457 P N F R T N I 2 CQ
G535 P K F S T N I 2 CQ
G126 P N F R T N I 2 ACPR (CQ-SP)
G1040 P N F R T N I 2 ACPR (ART-SP)
G743 P N F R T N I 2 CQ
G2028 P N F R T N I 2 ACPR (ART-SP)
G2041 P N F R T N I 2 ACPR (ART-SP)
G2067 P N F R T N I 2 ACPR (ART-SP)
G2090 P N L S T T I 2 ACPR (ART-SP)
G2091 P K F S T N I 2 ACPR (ART-SP)
G2099 P N F R T N I 2 ACPR (ART-SP)
G2110 P N F R T N I 2 ACPR (ART-SP)
G273 P N L R T T I 3 CQ
G852 P N L R M T I 4 LTF (SP)
G1015 P N L R M T I 4 LTF (ART-SP)
G2042 P N L R M T I 4 LTF (ART-SP)
G2095 P N L R M T I 4 ACPR (ART-SP)
G2022 P/S N F/L R/S M/T T I Mixed (1 and 4) ACPR (ART-SP)
a Wild-type amino acids are in roman-type, previously described polymorphisms are in italics, and novel polymorphisms are in bold type.
b LTF, late treatment failure; CQ alone, treated only with CQ.
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randomization of the CQ studies by day of attendance, and the
presence of mixed infections. Furthermore, the slow parasite
killing with SP may have only delayed rather than eradicated
emerging parasitemia from either the recrudescence of initial
infection or the first relapse. Current WHO efficacy protocols
(45) fail to detect delayed treatment failure beyond day 28.
However, the prevention of the expected relapses and the
hematological recovery seen (32) do provide evidence for a
therapeutic effect of SP against P. vivax in Papua. Although
patient numbers were small, the preliminary finding of the
improved efficacy of CQ-SP over CQ alone for vivax malaria
provides further evidence for the modest efficacy of SP in
Papua. While a study with larger numbers may confirm this,
such a study would now be difficult to justify in Papua: the high
rates of P. vivax and P. falciparum resistance to CQ (2, 3, 5, 21,
28, 38) and the poor efficacy of CQ-SP against P. falciparum in
both northern (38) and southern (8) Papua render the combi-
nation of CQ-SP no longer a rational option for malaria treat-
ment in this region.
Double (at positions 58 and 117) and quadruple (at positions
57, 58, 61, and 117) mutations in the Pvdhfr gene were common
in the P. vivax isolates from Papua but were not found further
west in NTT Province. Rates of CQ and SP resistance of P.
falciparum are also higher in Papua Province than in the NTT
province (38, 40; E. Tjitra, S. Suprianto, M. Dyer, B. J. Currie,
and N. M. Anstey, abstract, Am. J. Trop. Med. Hyg. 61[Suppl.]:
286-287, 1999), resulting in greater use of SP as a second line
of therapy for P. falciparum infection in Papua and greater
drug pressure on the dhfr gene of both species. Mass drug
administration of CQ and pyrimethamine in the former Neth-
erlands New Guinea in the late 1950s (15, 19), including the
addition of pyrimethamine to salt (15, 20), may also have
contributed to the high frequency of Pvdhfr mutations in Papua
compared with that in NTT.
Mutations at four amino acid positions in PvDHFR, P33L,
F57L, S58R, and S117N, have been reported previously (12,
16). Two types of PvDHFR alleles encoding either a double
mutation of S57R-S117N or a triple mutation of F57L-S58R-
S117N were observed in Thai and Indian samples. A single
mutation of P33L was observed only in samples from Mada-
gascar and Comoros islands (16). The PvDHFR double and
triple mutant alleles have been linked to lower parasite reduc-
tion ratios (16). However, these studies have not found an
association between Pvdhfr gene mutations and treatment fail-
ure (16). In the Papuan samples, we identified seven mutations
in PvDHFR at six positions: P33S, N50K, F57L, S58R, T61M,
and S117N/T, which correspond to amino acids 44, 51, 58, 59,
62, and 108 in PfDHFR, respectively. Among the seven muta-
tions observed in PvDHFR, four have been reported in
PfDHFR (N51I, C59R, and S108N/T) to result in resistance to
pyrimethamine and cycloguanil (7, 14, 25, 26). The single
S108N and S108T mutations result in increased resistance to
pyrimethamine and cycloguanil, respectively. Combinations of
S108N with the mutations N51I, C59R, and I164L were found
to confer higher levels of resistance to pyrimethamine (7).
Molecular modeling predicted that S108 is located at the active
site in PfDHFR and that the S108N/T mutation results in
displacement of pyrimethamine and cycloguanil from the bind-
ing site (11). Mutations at positions 51 and 59 were predicted
to be distant from the active site but may affect the admission
of the drug to the binding site (11). Since PvDHFR is highly
homologous to PfDHFR in sequence, we would expect that it
shares a high structure similarity with PfDHFR and that the
mutations N50K, S58R, and S117N/T in PvDHFR have effects
similar to those of the corresponding mutations in PfDHFR.
Indeed, the Escherichia coli-expressed PvDHFR with the S58R
and S117N mutations has been shown to confer resistance to
both pyrimethamine and cycloguanil (18, 36). Mutations cor-
responding to P33S, F57L, and T61M have not been reported
in PfDHFR. Recently, Leartsakulpanich et al. reported that E.
coli-expressed PvDHFR with the F57L mutation confers a
strong resistance to pyrimethamine and cycloguanil and that
PvDHFR with the P33L mutation confers a small increase in
resistance to pyrimethamine but not to cycloguanil (18). The
effect of the T61M mutation requires further investigation.
Seven PvDHFR mutant alleles were identified from the Pap-
uan samples that encoded the following mutations: S117N
alone, S58R-S117N, N50K-S117N, S117T alone, F57L-S117T,
F57L-S58R-S117T, and F57L-S58R-T61M-S117T. These ob-
served allele structures strongly suggest that two different step-
wise drug selection processes have occurred in the area: (i)
S117N to S58R-S117N or N50K-S117N and (ii) S117T to
F57L-S117T, then to F57L-F58R-S117T, and finally F57L-
F58R-T61M-S117T (Fig. 1).
Since treatment failure with SP-containing regimens was
significantly higher with the mutant allele of PvDHFR encod-
ing F57L-S58R-T61M-S117T, it appears that the quadruple
mutation confers higher resistance to SP than does the mutant
allele encoding a double mutation (S58R-S117N or N50K-
S117N). Although the sample number is small, the results
indicate that the allele encoding a quadruple mutation may be
used as a marker to predict clinical outcome following treat-
ment with SP-containing regimens.
It is interesting that mutations of N50K and T61M have not
been reported for PvDHFR and that the allele encoding the
quadruple mutation F57L-S58R-T61M-S117T and the allele
encoding the double mutation N50K-S117N have so far not
been reported for other areas where malaria exists. One ex-
planation may be that previous studies performed restriction
fragment length polymorphism analysis for the presence or
absence of the known mutations and did not perform sequenc-
ing, which may lead to an underestimation of the mutations in
the samples. The second explanation may be that a different
selection pressure was exerted in these areas. In P. falciparum,
TABLE 4. Relationship between the number of mutations in the
Pvdhfr gene and clinical outcome following treatment of
vivax malaria with an SP-containing regimen
No. of
mutations
No. (%) of
isolatesa
No. (%) of isolates
with ACPR with
SP-containing regimen
0 6 (21) 4/5 (83)
1 3 (11) 2/2 (100)
2 13 (46) 9/9 (100)
3 1 (4) —b
4 5 (18) 2/5 (40)
Total 28
a Includes isolates from patients with mixed infections.
b —, not treated with SP-containing regimen.
VOL. 46, 2002 ARTESUNATE–SULFADOXINE-PYRIMETHAMINE IN P. VIVAX 3951
 o
n
 Septem
ber 3, 2013 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
the S108N mutation is primarily associated with py-
rimethamine resistance (7, 26), while S108T, combined with
A16V, has been associated with cycloguanil resistance (25).
S108T mutations have been found mainly in laboratory lines
and are not commonly seen in field isolates (22, 34). It has
been proposed that the S108T mutation may result in a signif-
icant loss of fitness to the mutant parasite, rendering mutant
parasites less competitive than other parasites under the field
conditions. In our set of P. vivax samples, S117T mostly oc-
curred in tandem with F57L or with F57L-S58R-T61M. These
additional mutations are likely to confer a higher level of
resistance to pyrimethamine than S117T alone does and may
compensate for the loss of fitness resulting from the S117T
mutation.
In conclusion, treatment with ART-SP resulted in rapid
clearance of parasites and fever and a high 28-day cure rate for
vivax malaria in Papua, which is similar to that previously
found with P. falciparum (39). At least two mutations in
PvDHFR were found in the majority of Papua Province iso-
lates with the newly described quadruple mutation associated
with treatment failure. Rapid emergence of dhfr mutations is
known to occur in P. falciparum in the face of continued use of
antifolate monotherapy (27, 35) and is likely to also occur with
P. vivax. The addition of ART to SP may delay the emergence
of pyrimethamine-resistant P. vivax and SP-resistant P. falci-
parum. However, the continued use of SP in empirical mono-
therapy for clinical malaria in Papua since these studies were
performed makes the progression of dhfr gene mutations
likely in both species and threatens the future efficacy of this
combination for both vivax and falciparum malaria.
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